中国医学前沿杂志（电子版）2017，Vol.9Issue(12)：134-138,5.DOI:10.12037/YXQY.2017.12-30
孟鲁司特钠联合布地奈德混悬液对咳嗽变异性哮喘患儿呼吸功能及血IgE和EOS的影响分析
Effect of Montelukast sodium combined with Budesonide suspension on respiratory function, IgE and EOS in children with cough variant asthma
摘要
Abstract
Objective To analyze the effects of Montelukast sodium combined with Budesonide suspension on respiratory function, immunoglobulin E (IgE) and eosinophil (EOS) in children with cough variant asthma (CVA), and to investigate its clinical value. Method A total of 120 children with CVA treated in our hospital from March 2015 to March 2017 were enrolled in this study. According to the random number table method, they were divided into observation group and control group, 60 cases in each group, all of the children were treated with Budesonide suspension inhalation therapy, observation group children added Montelukast sodium oral, two groups were treated for 2 months. The changes of respiratory function, IgE and EOS were recorded before and after treatment between the two groups, and the efficacy and safety of the two treatment regimens were evaluated according to the occurrence of acute symptoms and the change of symptom scores before and after treatment. Result After treatment, the frequency of acute symptoms in the two groups were significantly lower than before treatment (P < 0.05), the childhood asthma control test (C-ACT) scores were significantly higher than those before treatment (P<0.05), and the frequency of daytime and nighttime cough of observation group were lower than control group (P<0.05), the C-ACT score was significantly higher than control group (P<0.05). After treatment, forced expiratory volume in first second (FEV1), FEV1% predicted value, forced vital capacity (FVC), FEV1/FVC and peak expiratory flow (PEF) of the two groups were all higher than before treatment (P<0.05), the above indicators of observation group were all higher than control group (P < 0.05). After treatment, the IgE and EOS of the two groups were significantly lower than those before treatment (P<0.05). The IgE and EOS of observation group were significantly lower than control group (P < 0.05). The total effective rate of observation group was significantly higher than control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (χ2=0.152, P>0.05). Conclusion Montelukast and Budesonide can be complementary and mutual cooperation, advantage in the treatment of CVA, which can effectively improve respiratory function and decrease the levels of IgE and EOS in peripheral blood of absolute value. Therefore, the clinical symptoms of children can be further alleviated on the premise of ensuring the safety of the treatment. It is worthy to be popularized as a safe and reliable treatment plan.关键词
孟鲁司特钠/布地奈德/咳嗽变异性哮喘/呼吸功能/免疫球蛋白E/嗜酸性粒细胞Key words
Montelukast sodium/Budesonide/Cough variant asthma/Respiratory function/Immuno-globulin E/Eosinophils引用本文复制引用
唐卫珍,徐红梅,徐吉成,严黛红..孟鲁司特钠联合布地奈德混悬液对咳嗽变异性哮喘患儿呼吸功能及血IgE和EOS的影响分析[J].中国医学前沿杂志（电子版）,2017,9(12):134-138,5.基金项目
2016年度苏州市科技计划项目(SYSD2016111) （SYSD2016111）
